Literature DB >> 26717798

Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases.

Annalina Avram1, Cátia Duarte2, Maria José Santos3, Charalampos Papagoras4, Konstantinos Ritis5, Roberto Scarpioni6, Wolfgang A Schmidt7, Panagiotis Skendros8.   

Abstract

A subgroup of patients with gouty arthritis have a chronic recurring form that is particularly difficult to treat. Such patients experience repeated flares and often have abundant tophi. Many also have underlying comorbidities, such as renal impairment, cardiovascular disease, gastrointestinal disorders, obesity, and hypertension, which contraindicate the use of standard anti-inflammatory medications. Five patients with difficult to treat gouty arthritis who were either candidates and/or treated with anti-IL therapy are described.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anakinra; Anti-IL-1β therapy; Canakinumab; Gouty arthritis; Tophaceous gout

Mesh:

Substances:

Year:  2015        PMID: 26717798     DOI: 10.1016/S1297-319X(15)30004-X

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  1 in total

1.  [Rare manifestations of axial skeleton gouty arthropathy].

Authors:  H Bastian; M Worsch; A Huppertz; A Krause; W A Schmidt
Journal:  Internist (Berl)       Date:  2017-02       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.